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Abstract 
Background. Clinical risk scores, CHADS2 and CHA2DS2‐VASc scores, are the established tools for assessing stroke 
risk in patients with atrial fibrillation (AF).  
Aim. The aim of this study is to assess concordance between manual and computer‐based calculation of CHADS2 and 
CHA2DS2‐VASc scores, as well as to analyse the patient categories using CHADS2 and the potential improvement on 
stroke risk stratification with CHA2DS2‐VASc score.  
Methods. We linked data from Atrial Fibrillation Spanish registry FANTASIIA. Between June 2013 and March 2014, 
1318 consecutive outpatients were recruited. We explore the concordance between manual scoring and computer‐
based calculation. We compare the distribution of embolic risk of patients using both CHADS2 and CHA2DS2‐VASc 
scores  
Results. The mean age was 73.8 ± 9.4 years, and 758 (57.5%) were male. For CHADS2 score, concordance between 
manual scoring and computer‐based calculation was 92.5%, whereas for CHA2DS2‐VASc score was 96.4%. In 
CHADS2 score, 6.37% of patients with AF changed indication on antithrombotic therapy (3.49% of patients with no 
treatment changed to need antithrombotic treatment and 2.88% of patients otherwise). Using CHA2DS2‐VASc score, 
only 0.45% of patients with AF needed to change in the recommendation of antithrombotic therapy.  
Conclusion. We have found a strong concordance between manual and computer‐based score calculation of both 
CHADS2 and CHA2DS2‐VASc risk scores with minimal changes in anticoagulation recommendations. The use of 
CHA2DS2‐VASc score significantly improves classification of AF patients at low and intermediate risk of stroke into 
higher grade of thromboembolic score. Moreover, CHA2DS2‐VASc score could identify ‘truly low risk’ patients 
compared with CHADS2 score.  
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Introduction 
Atrial fibrillation (AF) is the most common cardiac rhythm disorder in general population which is 
associated with high risk of mortality and morbidity from stroke events.
1
 Patients who survive a non‐fatal 
stroke are more likely to suffer recurrences.
2
 Stroke risk in AF is not homogeneous and is closely 
correlated with bleeding risk.
3, 4 
In this context, risk stratification schemes try to help in clinical decision 
making.
5
 
 
The CHADS2 score (Table 1) was developed to identify AF patients with high risk for stroke.
5 
Despite 
stroke risk in AF being a continuum, the most risk stratification schemes have been used to ‘artificially’ 
categorise patients into low risk (CHADS2 = 0), moderate risk (CHADS2 = 1) and high risk (CHADS2 ≥ 
2) stroke strata.
2, 6
 The CHADS2 schema is widely used due to its simplicity and ease, but different 
analysis showed that the classical CHADS2 score generates a large intermediate risk group (>60%), and a 
CHADS2 = 0 does not reliably identify AF patients who are at low risk.
1, 6
 In 2009 new Birmingham 
schema – CHA2DS2‐VASc (Table 1) was proposed, being more inclusive of common stroke risk factors 
in AF. CHA2DS2‐VASc significantly improves the predictive value of the CHADS2, and this score has 
been used as the basis of treatment recommendations.
1, 6 
CHA2DS2‐VASc score consistently performs 
better accuracy in the identification of truly low‐risk patients (CHA2DS2‐VASc = 0) with AF who do not 
need any antithrombotic therapy
3, 7; 
and this score performs at least as good as CHADS2 in identifying 
high‐risk patients (CHA2DS2‐VASc ≥2) who need antithrombotic therapy (Class I recommendation)
.8
 
Also the CHA2DS2‐VASc score classifies only a small proportion (<15.0%) as moderate risk (CHA2DS2‐
VASc = 1) when oral anticoagulation should be considered (Class IIa recommendation).
1, 7, 9
 CHA2DS2‐
VASc scheme successfully predicts cardiovascular events and mortality, but not major bleeds.
10
 Indeed, 
HAS‐BLED score is better for predicting major bleeding than CHADS2 or CHA2DS2‐VASc. So it is 
important the knowledge and use of both thrombotic and bleeding risk schemes.
4
 
Table 1. Assessment of risk score with CHADS2 and CHA2DS2‐VASc score
1, 17 
CHADS2 Score CHA2DS2‐VASc Score 
    
Congestive heart failure 1 Congestive heart failure 1 
Hypertension 1 Hypertension 1 
Age ≥75 years 1 Age ≥75 years 2 
Diabetes mellitus 1 Diabetes mellitus 1 
Stroke/TIA 2 Stroke/TIA 2 
Vascular disease 1 
Aged 65–74 years 1 
Sex category (female) 1 
Maximum score 6 Maximum score 9 
    
 
Despite the evidence in favour of antithrombotic therapy for stroke prevention, there are still many 
patients with AF underdiagnosed or undertreated.
11
 Euro Heart Survey in AF
12
 provided a detailed 
description of antithrombotic drugs related to stroke risk stratification schemes in real life cardiology 
practice. This survey showed how antithrombotic therapy prescription was quite high throughout all risk 
categories, irrespective of the stroke risk stratification scheme used. This suboptimal use may, among 
several reasons, be related to unawareness among clinicians to guidelines and risk stratification schemes. 
In the last focused update of the European Society of Cardiology guidelines for the management of AF 
strongly recommend a practice shift towards greater focus on the identification of patients without 
thromboembolic risk factors who do not benefit from antithrombotic therapy instead to trying to focus on 
identifying high‐risk patients.13, 14 At present, CHA2DS2‐VASc risk score has largely been validated in 
several cohorts of patients with AF around the world to correctly reclassified thromboembolic risk in 
patients with intermediate risk with CHADS2 because despite the modest degree of the risk discrimination 
improvement, the clinical consequence of reclassification could be substantial.
15, 16
 
 
The aim of this study was to analyse the quality and applicability assessment of stroke risk scores in 
clinical practice and its influence on antithrombotic therapy in a wide cohort through FANTASIIA 
(Fibrilación Auricular: influencia del Nivel y Tipo de Anticoagulación Sobre la incidencia de Ictus y 
Accidentes hemorrágicos) national registry. Our objective was to assess concordance between manual and 
computer‐based calculation of CHADS2 and CHA2DS2‐VASc scores. In addition, this study aims to 
analyse that patients categorised as low and intermediate risk of stroke using CHADS2 should improve 
stroke risk stratification with CHA2DS2‐VASc score.  
Methods 
Registry data sources 
For this study, we linked data from Atrial Fibrillation Spanish registry FANTASIIA. FANTASIIA 
registry holds information on current situation of AF non‐valvular in Spanish population. This study 
assesses incidence of thrombotic and bleeding events at 3 years follow up in non‐valvular AF, type of 
antithrombotic drugs (vitamin K antagonists (VKA) or new oral anticoagulants) and appropriate 
recommendation of antithrombotic therapy. Patients with rheumatic mitral valve disease or patients with 
prosthetic heart valves were excluded. 
Study population 
We recruited 1318 consecutive outpatients diagnosed as non‐valvular AF from June 2013 to March 
2014. This prospective national multicenter observational study included all consecutive patients older 
than 18 years with non‐valvular AF who were treated with oral anticoagulation (VKA or new oral 
anticoagulants) at least 6 months before a patient's enrolment. Patient management was according to usual 
local practice without further intervention. The CHADS2 and CHA2DS2‐VASc scores were calculated for 
each patient with the relevant variables collected at baseline. These scores were calculated both manually 
and automatically with computer application.  
 
The FANTASIIA registry complied with the Declaration of Helsinki and the study protocols were 
approved by San Juan Hospital institutional ethics boards and the Ethic Committee of every participant 
centre. All participants provided written informed consent. 
Statistical analysis 
Continuous variables were tested for normality by the Kolmogorov–Smirnov test. Continuous 
variables are presented as a mean ± SD or median (interquartile range, as appropriate, and categorical 
variables as a percentage). Kolmogorov–Smirnov test was used to check for normal distribution of 
continuous data. Unpaired t‐test or chi‐square test was used to compare differences between the two 
groups. A P value <0.05 was accepted as statistically significant. Statistical analyses were performed 
using spss version (Chicago, IL, USA).  
  
Results 
Baseline clinical characteristics of the patients are shown in Table 2. A total of 1318 patients were 
included by 85 Spanish investigators (80.9% cardiologists, 10.9% primary care physicians and 8.3% 
internal medicine specialists). The mean age was 73.8 ± 9.4 years, and 758 (57.5%) were male. 
Hypertension was the most prevalent stroke risk factor (81.0%) followed by hypercholesterolaemia 
(54.0%) and diabetes (29.0%). Other remarkable comorbidities were ischaemic stroke (15.9%) and major 
bleeding (3.3%). At the time of the initial visit, the majority of patients (77.1%) were treated with VKA: 
927 (71.9%) with acenocoumarol (the most widely oral anticoagulant used in Spain) and 67 patients 
(5.2%) with warfarin. New oral anticoagulants were used in 22.9% of patients with AF. 
Table 2. Baseline clinical characteristics of studied 
population† 
Patients n = 1318 
  
Female sex 560 (42.5) 
Age, years 73.8 ± 9.4 
Age ≥ 75 years 689 (52.3) 
Cardiovascular risk factors no. (%) 
Hypertension 1068 (81.0) 
Hypercholesterolaemia 711 (54.0) 
Diabetes mellitus 386 (29.3) 
Current smoker 60 (4.6) 
Concomitant disease no. (%) 
Renal impairment 251 (19.0) 
Hepatic impairment 13 (1.0) 
Vascular disease 92 (7.0) 
Previous stroke 210 (15.9) 
Thyroid diseases 173 (13.1) 
Current alcoholic/drugs consumption 210 (15.9) 
Major bleeding events 44 (3.3) 
Previous heart disease 629 (47.7) 
Heart failure 376 (28.5) 
Coronary heart disease 245 (18.6) 
CHADS2 score  no. (%) 
CHADS2 = 0  64 (4.9) 
CHADS2 = 1  318 (24.1) 
CHADS ≥ 2  936 (71.0) 
CHA2DS2‐VASc score  no.(%) 
CHA2DS2‐VASc = 0  16 (1.2) 
CHA2DS2‐VASc = 1  86 (6.5) 
CHA2DS2‐VASc ≥ 2  1216 (92.3) 
HAS‐BLED score no. (%) 
HAS‐BLED ≥ 3 363 (27.7) 
Concomitant treatment‡  no. (%) 
Diuretics 766 (59.4) 
ACE (angiotensin‐converting enzyme) 
inhibitors 
402 (31.2) 
Angiotensin receptor blockers 529 (41.0) 
Statins 726 (56.3) 
Table 2. Baseline clinical characteristics of studied 
population† 
Patients n = 1318 
Antiplatelet therapy 128 (9.9) 
Antithrombotic treatments‡  no. (%) 
Vitamin K antagonists 994 (77.1) 
Acenocoumarol 927 (71.9) 
Warfarin 67 (5.2) 
New oral anticoagulants 296 (22.9) 
  
 
† Data are presented as observed number (no. (%)) or mean 
± standard deviation (SD).  
‡ Available for 1290 patients.  
CHADS, congestive heart failure, hypertension, age ≥ 75 
years, diabetes mellitus, stroke; HAS‐BLED, hypertension, 
abnormal renal/liver function, stroke, bleeding history or 
predisposition, labile international normalised ratio, elderly, 
drugs/alcohol concomitantly; VASc, vascular disease, aged 
65–74 years, sex category. 
 
 
 
 
 
 
 
 
 
 
 
 
The CHADS2 score classified 4.9% as low risk (score = 0), 24.1% classified as intermediate risk 
(score = 1) and 71.0% classified as high risk (score ≥2). The CHA2DS2‐VASc score classified 1.2% as 
low risk (score = 0), 6.5% classified as intermediate risk (score = 1) and 92.3% classified as high risk 
(score ≥ 2). In this registry, 27.7% of patients showed high bleeding risk, assessed by HAS‐BLED score 
(score ≥ 3) (Fig. 1). 
 
 
 
Figure 1. Distribution of stroke risk categories according to CHADS2 ( ), CHA2DS2‐VASc ( ) and HAS‐BLED ( ) scores in all 
study patients. The number (%) is shown in each bar.  
Concordance between manual and computer‐based calculation of risk scores 
For CHADS2 score, overall concordance between manual scoring and computer‐based calculation was 
92.5%; whereas for CHA2DS2‐VASc score, the concordance between manual and computer‐based 
scoring was 96.4% (Table 3). We found a strong concordance between the manual and the computer‐
based score calculation. These results lead to a change in recommendation of oral anticoagulation. In 
CHADS2 score, 6.37% of patients with AF changed indication on antithrombotic therapy (3.49% of 
patients with no treatment changed to need antithrombotic treatment and 2.88% of patients otherwise). 
Using CHA2DS2‐VASc score, only 0.45% of patients with AF needed to change in the recommendation 
of antithrombotic therapy.  
  
Table 3. Concordance between manual and computer‐based calculation of risk scores 
 
CHADS2 manual   
CHA2DS2‐VASc manual  
          
CHADS2 app.   0 1 ≥2 CHA2‐VASc app.   0 1 ≥2 
0 50 5 0 0 10 2 0 
1 10 269 38 1 5 61 13 
≥2 2 44 895 ≥2 1 21 1200 
          
 
CHADS, congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke; VASc, vascular disease, aged 65–74 years, 
sex category. 
Comparison between CHADS2 and CHA2DS2‐VASc risk scores  
The distribution of both CHADS2 and CHA2DS2‐VASc scores is demonstrated in Table 4. Of the 64 
patients classified as low risk with CHADS2 schema (score = 0), only 16 patients were classified at low 
risk with CHA2DS2‐VASc schema (score = 0), while 30 patients could be estimated at intermediate risk 
based on CHA2DS2‐VASc score = 1 (9 women <65 years, 20 men between 65 and 74 years and 1 man 
with vascular disease). Finally, 18 patients were reclassified into high embolic risk with a CHA2DS2‐
VASc = 2 (15 women between 65 and 74 years and 3 men with vascular disease).  
Table 4. The number of patients with each CHADS2 score and the number of 
patients changed to each new score when evaluated by CHA2DS2‐VASc score 
Risk scores Number of patients 
  
CHADS2 = 0  64 
CHA2DS2‐VASc = 0  16 
CHA2DS2‐VASc = 1  30 
CHA2DS2‐VASc = 2  18 
CHADS2 = 1  318 
CHA2DS2‐VASc = 0  0 
CHA2DS2‐VASc = 1  56 
CHA2DS2‐VASc = 2  137 
CHA2DS2‐VASc = 3  123 
CHA2DS2‐VASc = 4  2 
  
 
CHADS, congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, 
stroke; VASc, vascular disease, aged 65–74 years, sex category. 
 
  
Regarding 318 patients classified as intermediate risk with CHADS2 schema (score = 1), only 56 
patients were classified as intermediate risk with the new risk scale, CHA2DS2‐VASc = 1, whereas 137 
patients were reclassified as high risk, CHA2DS2‐VASc score = 2 (12 women <65 years, 88 men between 
65 and 74 years, 27 men >75 years and 10 men <65 years with vascular disease). A total of 123 patients 
were reclassified into higher grade of thromboembolic risk CHA2DS2‐VASc = 3 (73 women between 65 
and 74 years, 32 women >75 years, 13 men between 65 and 74 years with vascular disease and 5 men >75 
years with vascular disease). Finally, two patients with CHADS2 score = 1 were reclassified into 
CHA2DS2‐VASc = 4 (two women between 65 and 74 years with vascular disease).  
 
Of our cohort, 81.1% of patients with CHADS2 score = 0–1, and 23.0% of all patients were 
reclassified into higher grade of thromboembolic risk with CHA2DS2‐VASc score.  
 
After reclassification, patients with CHA2DS2‐VASc ≥ 2 required antithrombotic therapy and patients 
with CHA2DS2‐VASc = 1 were considered to start anticoagulation treatment. Nevertheless, latest 
European guidelines
6
 recommend female patients with CHA2DS2‐VASc = 1 due to gender alone as a 
single risk factor (nine women in our study) would not need anticoagulation if they clearly fulfil only the 
criteria of ‘age < 65 years’. These women younger than 65 years have a low risk for stroke (0.7% per 
year) and do not need anticoagulation treatment.
17
 
Discussion 
The findings of this study confirm that Spanish physicians correctly calculate thromboembolic risk 
scores. Manual CHADS2 and CHA2DS2‐VASc risk scores showed excellent concordance with both 
computer‐based risk scores.  
 
The major advantage to use CHADS2 score has always been its simplicity, because this score is a 
straightforward algorithm consisting of a small number of variables. Most clinicians who manage patients 
with AF become familiar with CHADS2 score as a guide to stroke risk due to its simplicity. Nevertheless, 
this score does not discriminate particularly well between very low‐risk patients and intermediate risk 
patients with AF. Therefore, CHA2DS2‐VASc has been included in guidelines to be more inclusive of 
common stroke risk factors with three new variables. However, CHA2DS2‐VASc score calculation is 
more complex and may involve errors.
18
 
 
In this study, we analysed the comparison between manual and computer‐based calculation of both 
CHADS2 and CHA2DS2‐VASc scores. We have seen that there is a high correlation between scores 
obtained by computer‐based and manual calculation.  
For CHADS2 score, there is a 92% of concordance, while for CHA2DS2‐VASc score there is a 96.4% 
of concordance between both systems. Despite CHADS2 score is simpler to calculate, in our study it has 
been observed greater concordance in the calculation of CHA2DS2‐VASc score. Maybe these results 
showed the knowledge and adherence of Spanish physicians to the last guidelines and clinical practices 
for the treatment of AF.  
 
These results lead to a change in antithrombotic therapy in 3.49% of patients whose stroke risk was 
calculated with CHADS2 score and only 0.45% of patients with CHA2DS2‐VASc score. These findings 
show minimal changes in anticoagulation recommendations according to the manual or computer‐based 
scoring system used with CHA2DS2‐VASc score, but for CHADS2 score this change in anticoagulation 
recommendation is higher, being close to 5%.  
 
In addition, we reported that CHA2DS2‐VASc score can further refine stroke risk stratification better 
than CHADS2 score, and this scoring system may be an useful tool to predict with more precision 
thromboembolic events in patients with AF. In our study, using CHADS2 score we identified 24.1% of 
patients with intermediate risk (CHADS2 score = 1) and 71.0% of patients with AF were identified with 
high‐thromboembolic risk (CHADS2 ≥ 2). When CHA2DS2‐VASc score was used to stratify stroke risk, 
the intermediate risk (CHA2DS2‐VASc = 1) decreased to 6.5 and 92.3% of all patients of AF were 
classified as high risk with CHA2DS2‐VASc score (score ≥2). This study has shown that when we 
reclassified patients with CHADS2 score into CHA2DS2‐VASc score, more than 20% of all patients were 
reclassified to a high‐risk stratum by CHA2DS2‐VASc score. In the controversial low/intermediate group 
of CHADS2 0–1 score, 81.1% of patients in this group were reclassified into higher grade of 
thromboembolic risk with CHA2DS2‐VASc score. Importantly, we estimated 4.9% patients at low risk by 
CHADS2 score (CHADS2 = 0), whereas only 1.2% of all patients with AF were classified into low risk 
with CHA2DS2‐VASc. These findings are consistent with the increasing literature from multiple different 
cohorts that CHA2DS2‐VASc score is better than CHADS2 specially in identification of truly low‐risk 
patients (CHA2DS2‐VASc = 0) who may not need any thrombotic therapy and CHA2DS2‐VASc is better 
in reducing patients classified in intermediate risk score.
1, 15
 Our results are consistent with American8 
and European
6
 clinical guidelines for the management of patients with AF. Both guidelines now 
recommend the use of CHA2DS2‐VASc score for risk stratification because CHA2DS2‐VASc score 
identified those patients who are truly at low risk. As a consequence, fewer patients were assigned to the 
low‐risk category with CHA2DS2‐VASc score than when using CHADS2 score. Our clinical data showed 
that 382 (28.9%) patients were classified as CHADS2 0–1, whereas only 102 (7.7%) were classified as 
CHA2DS2‐VASc 0–1 score. Moreover, the nationwide Danish registry showed, similar to FANTASIIA 
registry, that event in patients categorised as ‘low risk’ using a CHADS2 score = 0, the CHA2DS2‐VASc 
score significantly improved the predictive value of the CHADS2 score alone.
7
 
 
Indeed, there is a change of perspective. The goal of the CHA2DS2‐VASc score is to identify the truly 
low‐risk patients who do not require oral anticoagulation therapy.13 Multiple studies have demonstrated 
that physicians do not adhere well to the current anticoagulation guidelines.
19 
In the study of validation of 
CHA2DS2‐VASc, a Danish cohort, including 47 576 AF patients with CHADS2 score 0–1 without 
warfarin treatment, thromboembolic events occurred at 3.49%/year compared with 0.84%/year and 
1.79%/year in the patient groups reclassified as having CHA2DS2‐VASc scores of 0 and 1 respectively.
10
 
These results confirm that patients with CHADS2 score of 0 were not all at low risk and anticoagulation 
decision based simply on CHADS2 score may underestimated the real risk in patients with AF, and the 
use of CHA2DS2‐VASc score significantly improves reclassification of AF patients. The clinical 
consequence of this reclassification is substantial to start anticoagulation treatment. In our study, 
according to the latest European guidelines on AF,
6 
using CHADS2 score 71.0% of patients with AF 
would have the recommendation to start oral anticoagulation, whereas using CHA2DS2‐VASc score, 
92.3% of patients with AF (CHA2DS2‐VASc ≥ 2) would have definite indication of start oral 
anticoagulation and 6.5% of patients with AF (CHA2DS2‐VASc = 1) would have consider indication of 
start oral anticoagulation therapy.
6
 
 
As mentioned above, CHADS2 score does not classify patients with low or intermediate 
thromboembolic risk correctly so any small change between scores obtained by computer‐based and 
manual calculation could involve a substantial change in indication of anticoagulation and, if calculated 
wrongly, may increase the thromboembolic risk in patients with AF.  
 
As a result of these findings, physicians correctly calculate risk scores, specifically CHA2DS2‐VASc 
score which is more complex because it includes more items, so the lack of adherence of clinical 
guidelines is due to other problems that need to be analysed in detail.  
Study limitations 
This article only reports the baseline data of the FANTASIIA registry and follow up is ongoing. A 
more comprehensive assessment of the data on the management and treatment of AF in population would 
be obtained from FANTASIIA long‐term registry which is scheduled in 2016. Most of our patients were 
under acenocoumarol. Acenocoumarol is the most common VKA used in Spain and shows a shorter half‐
life than warfarin (10 vs 36 h), but without differences on the time on therapeutic range. 
  
Conclusions 
We have found a strong concordance between manual and computer‐based score calculation of both 
CHADS2 and CHA2DS2‐VASc risk scores. These findings show minimal changes in anticoagulation 
recommendations according to the manual or computer‐based scoring system used above with CHA2DS2‐
VASc risk score. In addition, the use of CHA2DS2‐VASc score significantly improves the classification 
of AF patients at low and intermediate risk of stroke into higher grade of thromboembolic score, which 
would have indication of oral anticoagulation therapy, and could identify ‘truly low risk’ patients 
compared with the commonly used CHADS2 score, being consistent with the finding in several cohorts.  
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